ANVS401 Lessens Protein Buildup, Improves Cognition, Data Show

ANVS401 Lessens Protein Buildup, Improves Cognition, Data Show

314904

ANVS401 Lessens Protein Buildup, Improves Cognition, Data Show

Annovis Bio’s oral therapy ANVS401 lessened the accumulation of toxic forms of amyloid-beta and tau protein — two hallmarks of Alzheimer’s disease — and led to significant improvements in cognition in patients with early Alzheimer’s, data from a Phase 2a study show. Moreover, ANVS401 levels in the blood were in agreement with previous studies and the therapy was deemed safe, meeting both primary and secondary trial goals. It has also shown promising results for Parkinson’s disease…

You must be logged in to read/download the full post.